Individuals with germline mutations in one or more MMR proteins (i.e. MLH1, MSH2, MSH6, PMS2), known as Lynch Syndrome (LS) patients, have a higher risk for developing early-onset cancers in multiple tissues (19–21). This evidence concerns the gene MRC1 and cancer.